Nothing Special   »   [go: up one dir, main page]

NO20065227L - Menoklonale antistoff mot hepatocytt vekstfaktor - Google Patents

Menoklonale antistoff mot hepatocytt vekstfaktor

Info

Publication number
NO20065227L
NO20065227L NO20065227A NO20065227A NO20065227L NO 20065227 L NO20065227 L NO 20065227L NO 20065227 A NO20065227 A NO 20065227A NO 20065227 A NO20065227 A NO 20065227A NO 20065227 L NO20065227 L NO 20065227L
Authority
NO
Norway
Prior art keywords
growth factor
hepatocyte growth
antibody
menoclonal
pharmaceutical composition
Prior art date
Application number
NO20065227A
Other languages
English (en)
Inventor
Jin Kyong Kim
Yi-Chi Su
Lihong Wang
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065227(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of NO20065227L publication Critical patent/NO20065227L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sammendrag Oppfinnelsen er rettet på et nøytraliserende monoklonalt antistoff til hepatocyttvekstfaktor, en farmasøytisk blanding omfattende det samme, og fremgangsmåte for behandling omfattende at en pasient tilføres en slik farmasøytisk blanding, som for eksempel for å inhibere glioblasom.
NO20065227A 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor NO20065227L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
NO20065227L true NO20065227L (no) 2007-01-10

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065227A NO20065227L (no) 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor

Country Status (26)

Country Link
US (5) US20040208876A1 (no)
EP (2) EP2204191A1 (no)
JP (2) JP4594381B2 (no)
KR (1) KR101072736B1 (no)
CN (1) CN1964738A (no)
AT (1) ATE473760T1 (no)
AU (1) AU2004319276C1 (no)
BR (1) BRPI0418745A (no)
CA (1) CA2563080C (no)
CR (1) CR8698A (no)
CY (1) CY1110783T1 (no)
DE (1) DE602004028168D1 (no)
DK (1) DK1734995T3 (no)
ES (1) ES2346886T3 (no)
HK (1) HK1094167A1 (no)
HR (1) HRP20100521T1 (no)
IL (1) IL178474A (no)
MX (1) MXPA06011822A (no)
NO (1) NO20065227L (no)
NZ (1) NZ550324A (no)
PL (1) PL1734995T3 (no)
PT (1) PT1734995E (no)
RU (1) RU2361879C2 (no)
SI (1) SI1734995T1 (no)
WO (1) WO2005107800A1 (no)
ZA (1) ZA200609407B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
PT1648998E (pt) * 2003-07-18 2014-11-04 Amgen Inc Agentes de ligação específica ao factor de crescimento do hepatócito
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
CN101330929B (zh) 2005-10-14 2014-03-05 学校法人福冈大学 胰岛移植中的移植胰岛障碍抑制剂
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (en) * 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
CA2654025C (en) 2006-06-02 2016-08-02 Xoma Technology Ltd. Hepatocyte growth factor (hgf) binding proteins
ATE533787T1 (de) * 2006-06-02 2011-12-15 Aveo Pharmaceuticals Inc Hepatozytenwachstumsfaktor (hgf)-bindende proteine
CA2675625C (en) 2007-01-23 2016-09-13 Shinshu University Chronic rejection inhibitor
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
CA2723617A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CA2812744A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
SG194932A1 (en) 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
CZ303636B6 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
JP2014534410A (ja) 2011-09-09 2014-12-18 アムジエン・インコーポレーテツド 食道および胃癌患者における抗肝細胞増殖因子（「ｈｇｆ」）抗体の有効性を予測するためのｃ−ｍｅｔタンパク質の使用
JP2014530201A (ja) 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
CA2904743A1 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2258153C (en) 1996-07-03 2004-08-17 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US20050075488A1 (en) 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
WO2003057155A2 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
DE602004024536D1 (de) 2003-07-07 2010-01-21 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
PT1648998E (pt) * 2003-07-18 2014-11-04 Amgen Inc Agentes de ligação específica ao factor de crescimento do hepatócito
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
KR20080026562A (ko) 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
US7687063B2 (en) 2010-03-30
ATE473760T1 (de) 2010-07-15
MXPA06011822A (es) 2007-03-23
EP2204191A1 (en) 2010-07-07
JP2011012067A (ja) 2011-01-20
KR20070012711A (ko) 2007-01-26
JP2007532643A (ja) 2007-11-15
KR101072736B1 (ko) 2011-10-11
RU2006140257A (ru) 2008-05-20
PL1734995T3 (pl) 2010-12-31
DE602004028168D1 (de) 2010-08-26
EP1734995A1 (en) 2006-12-27
AU2004319276A1 (en) 2005-11-17
CA2563080A1 (en) 2005-11-17
BRPI0418745A (pt) 2007-12-11
CY1110783T1 (el) 2015-06-10
RU2361879C2 (ru) 2009-07-20
US20080019966A1 (en) 2008-01-24
EP1734995A4 (en) 2007-04-25
IL178474A0 (en) 2007-02-11
SI1734995T1 (sl) 2010-09-30
WO2005107800A1 (en) 2005-11-17
JP4594381B2 (ja) 2010-12-08
US20040208876A1 (en) 2004-10-21
AU2004319276C1 (en) 2011-03-03
HK1094167A1 (en) 2007-03-23
ES2346886T3 (es) 2010-10-21
AU2004319276B2 (en) 2010-08-26
CN1964738A (zh) 2007-05-16
CA2563080C (en) 2015-01-27
HRP20100521T1 (hr) 2010-10-31
US7494650B2 (en) 2009-02-24
PT1734995E (pt) 2010-08-18
DK1734995T3 (da) 2010-10-25
NZ550324A (en) 2009-12-24
IL178474A (en) 2011-04-28
US20090104192A1 (en) 2009-04-23
ZA200609407B (en) 2008-07-30
EP1734995B1 (en) 2010-07-14
CR8698A (es) 2007-12-17
US20120064066A1 (en) 2012-03-15
US20070160613A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
NO20064136L (no) Anti-epcam-immunglobuliner
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
DE602004020337D1 (de) Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
DK1838392T3 (da) Selenholdige medikamenter mod endotheliale vaskulære sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application